Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: codeine placebo Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

NCT01055704
View directory record Official record
Conditions
Gastric Motility Disorder
Interventions
Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Garlic Supplements on Opioids in Healthy Volunteers

NCT00499460
View directory record Official record
Conditions
Healthy, No Evidence of Disease
Interventions
garlic powder tablets, oxycodone
Dietary Supplement · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 21, 2026, 5:10 PM EDT
Terminated Phase 4 Interventional Results available

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

NCT00484718
View directory record Official record
Conditions
Osteoarthritis
Interventions
celecoxib, Oxycodone, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 21, 2026, 5:10 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

NCT05761860
View directory record Official record
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, OxyCODONE 2.5 mg Oral Tablet, Placebo oxyCODONE Oral Tablet, Oxytocin Nasal Spray (48 IU), Placebo Oxytocin Nasal Spray
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

NCT05447286
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NYX-783, Placebo, Oxycodone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 58 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 21, 2026, 5:10 PM EDT
Not listed Not applicable Interventional

Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals

NCT02136784
View directory record Official record
Conditions
Analgesic Response
Interventions
morphine sulfate, hydrocodone, hydromorphone HCI, oxycodone, buprenorphine, oral tablet placebo, sublingual tablet placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA

NCT02601027
View directory record Official record
Conditions
Breast - Female
Interventions
Transversus Abdominis Plane (TAP) block, Nimbus Infusion Pump IV Administration, Bupivacaine infusion, Acetominophen, Hydromorphone, Oxycodone, Ondansetron
Procedure · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

NCT01038609
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Acetaminophen, Morphine Extended Release, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Peoria, Arizona • Austin, Texas • San Marcos, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 21, 2026, 5:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

NCT05053126
View directory record Official record
Conditions
Abuse Potential
Interventions
Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg, pregabalin 450 mg with oxycodone 20 mg, oxycodone 20 mg, Placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 3 Interventional

A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy

NCT00402792
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

NCT00979953
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ADL5859, ADL5747, Oxycodone CR, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Daytona Beach, Florida • Stockbridge, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Reduction of Opioid Dose Using Conditioning & Open-Label Placebo (COLP) in Intensive Rehabilitation

NCT03906721
View directory record Official record
Conditions
Spinal Cord Injuries, Polytrauma, Burn Injury, Pain Management
Interventions
Placebo, Oxycodone, Essential Oil
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction

NCT03893175
View directory record Official record
Conditions
Impacted Third Molar Tooth, Pain, Acute
Interventions
Ibuprofen, Acetaminophen, Placebo, Oxycodone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aprepitant Effects on Oxycodone Response

NCT00999544
View directory record Official record
Conditions
Narcotic Abuse
Interventions
Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg, Oxycodone 0mg, p.o., Oxycodone 20mg, p.o., Oxycodone 40mg, p.o., Oxycodone 0mg, IN, Oxycodone 15mg, IN, Oxycodone 30mg, IN
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Results available

Are Opioids Needed After ACL Reconstruction

NCT04285853
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
Oxycodone, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
14 Years to 40 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee

NCT01366014
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ARRY-371797, p38 inhibitor; oral, Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral, Placebo; oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 85 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 21, 2026, 5:10 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

NCT04218409
View directory record Official record
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, Oxytocin nasal spray, Placebo Oxycodone, Placebo oxytocin, OxyCODONE 2.5 mg Oral Tablet
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans

NCT01500317
View directory record Official record
Conditions
Effects of 2 Mu-opiates on Gastrointestinal Transit
Interventions
Tapentadol, Oxycodone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 21, 2026, 5:10 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

NCT03880487
View directory record Official record
Conditions
Analgesia
Interventions
KP-1199, Placebo oral capsule, Oxycodone oral capsule
Drug
Lead sponsor
Kalyra Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 5:10 PM EDT